
Regeneron Pharmaceuticals (REGN): Growth Power, But Valuation Caps Upside
Regeneron posted 36% revenue growth and 70% EPS growth in Q3 2026, driven by record sales from Dupixent, EYLEA HD, and Libtayo. The stock still earns a Hold as valuation and franchise concentration temper the long-term story.








